All In Biotech

Free tool

FAERS Monitor: Miplyffa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214927 or its brand name (Miplyffa, Arimoclomol Citrate). Reports on generic versions are filed under their own applications.

Reports

46

Serious

16

35% of reports

Hospitalization

10

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea6
  • vomiting5
  • product size issue4
  • insomnia3
  • pneumonia aspiration3
  • death2
  • fall2
  • fatigue2
  • gait disturbance2
  • pneumonia2
  • product administration interrupted2
  • product distribution issue2
  • product use complaint2
  • seizure2
  • sepsis2

Reports by year received

View as table
YearReports
20211
202539
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,113 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product size issueSignal4340.5133.51,035
product administration interrupted2116.530.0128
product distribution issue298.625.4108
product use complaint258.115.062
pneumonia aspirationSignal354.918.4110
sepsis28.22.17
seizure27.92.06
insomniaSignal35.21.76
vomitingSignal54.92.112
gait disturbance24.81.23
diarrhoeaSignal64.32.012
pneumonia22.80.71
fall22.70.71
fatigue21.20.30
death21.10.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.